布雷斯洛厚度
医学
黑色素瘤
彭布罗利珠单抗
阶段(地层学)
辅助治疗
内科学
肿瘤科
皮肤病科
疾病
三级转介中心
病理
无容量
活检
生存分析
头皮
外科
癌症
组织病理学
粘膜黑色素瘤
存活率
胃肠病学
佐剂
置信区间
回顾性队列研究
有丝分裂指数
作者
Luisa Boeti,Laura Del Regno,Lucia Di Nardo,Maria Mannino,Alessandro Di Stefani,Laura Quattrini,Irina Ciobotariu,Marisa Salvi,Ketty Peris
出处
期刊:Dermatology
[Karger Publishers]
日期:2026-04-02
卷期号:242 (4): 435-442
摘要
INTRODUCTION: The recent approval of pembrolizumab and nivolumab for the adjuvant treatment of stage IIB-IIC cutaneous melanoma (CM) significantly improved the relapse-free survival probability of this patient population. Real-life data suggest that not all stage IIB and IIC CM patients will invariably undergo disease progression. There is a growing need for accurate patients' selection for whom adjuvant therapy is expected to be beneficial. The aim of this study was to investigate the baseline clinical and histopathological features associated with tumor recurrence in stage II CM patients in an Italian tertiary referral center. METHODS: Patients' clinical features and histopathological tumor characteristics were recorded at the time of melanoma diagnosis. Non-recurrent patients were defined based on a ≥5-year follow-up period; time to disease recurrence was calculated as the time from the diagnosis of the primary tumor until first evidence of melanoma relapse. RESULTS: A total of 103 stage II CM patients, with a median follow-up of 6.2 years, were included. Twenty-one of 103 (20.4%) patients recurred, of whom 15/21 (71.4%) showed disease progression to stage IV disease. Breslow thickness was significantly associated with CM recurrence, with a 70% increased probability of melanoma relapse per each unit increase in Breslow thickness (mm) (OR = 1.7; 95% CI: 1.05-2.7; p = 0.029). Histopathological evidence of ulceration and the mitotic rate did not show a significant association with melanoma progression. Breslow thickness was also associated with a reduced time from melanoma diagnosis to recurrence per each unit increase (mm) (p = 0.032) and with shorter disease-free survival probability (HR: 1.47; 95% CI: 1.05-2.06; p = 0.025). CONCLUSION: Breslow thickness is a relevant prognostic factor for CM recurrence. Further studies are needed to identify novel prognostic biomarkers.
科研通智能强力驱动
Strongly Powered by AbleSci AI